Search Results - "Næsdal, Jørgen"

Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management: A Prospective Observational Study by Bytzer, Peter, Pratt, Stephen, Elkin, Eric, Næsdal, Jørgen, Sörstadius, Elisabeth

“…Background Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that…”
Get full text

The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk by Pratt, Stephen, Thompson, Vincent J., Elkin, Eric P., Næsdal, Jørgen, Sörstadius, Elisabeth

“…Background While low-dose acetylsalicylic acid (ASA [aspirin]; 75–325 mg) is a mainstay of cardiovascular (CV) protection in patients at high risk of CV…”
Get full text

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors by SCHEIMAN, James M, YEOMANS, Neville D, AHLBOM, Henrik, NAESDAL, Jørgen, HAWKEY, Christopher, TALLEY, Nicholas J, VAKIL, Nimish, CHAN, Francis K. L, TULASSAY, Zsolt, RAINOLDI, Jorge L, SZCZEPANSKI, Leszek, UNG, Kjell-Arne, KLECZKOWSKI, Dariusz

“…Proton pump inhibitors reduce ulcer recurrence in non-steroidal anti-inflammatory drug (NSAID) users, but their impact in at-risk ulcer-free patients using the…”
Get full text

NSAID-associated adverse effects and acid control aids to prevent them : A review of current treatment options by NXSDAL, Jøgen, BROWN, Kurt

“…NSAIDs are central to the clinical management of a wide range of conditions. However, NSAIDs in combination with gastric acid, which has been shown to play a…”
Get full text

Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75–325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention: Perspectives from Patient Focus Groups by Margolis, Mary Kay, Halling, Katarina, Sörstadius, Elisabeth, Næsdal, Jørgen, Manson, Stephanie, Coyne, Karin

“…Background and objective: As upper gastrointestinal (GI) symptoms are common with the use of low-dose aspirin (low-dose acetylsalicylic acid [LDASA]; 75–325…”
Get full text

Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA by Stålhammar, Nils-Olov, Spiegel, Brennan M, Granstedt Löfman, Helena, Karlsson, Maria, Wahlqvist, Peter, Næsdal, Jørgen, Nelson, M Todd, Despiégel, Nicolas

“…Disease burden and associated costs are not well understood among patients with gastroesophageal reflux disease (GERD) who have persistent symptoms despite…”
Get full text

Low-Dose Aspirin Therapy for Cardiovascular Prevention: Quantification and Consequences of Poor Compliance or Discontinuation by Herlitz, Johan, Tóth, Peter P., Næsdal, Jørgen

“…Long-term therapy with low-dose aspirin (acetylsalicylic acid; ASA), 75–325 mg, is highly effective for the secondary prevention of cardiovascular (CV) events…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome by DROSSMAN, Douglas A, DANILEWITZ, Mervyn, NAESDAL, Jørgen, HWANG, Clara, ADLER, John, SILBERG, Debra G

“…To investigate the efficacy and safety of the 5-hydroxytrypamine 1A (5-HT(1A)) receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate…”
Get full text

Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs by Yeomans, Neville D., Hawkey, Christopher J., Brailsford, Wayne, Næsdal, Jørgen

“…Abstract Background: Low-dose acetylsalicylic acid (ASA; aspirin; 75-325 mg/day) is effective for the prevention of cardiovascular events, and its use in this…”
Get full text

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid: A Quantitative Study in Patients with Cardiovascular Risk by Moberg, Christina, Naesdal, Jørgen, Svedberg, Lars-Erik, Duchateau, Delphine, Harte, Nicola

“…Background: Low-dose acetylsalicylic acid (ASA; 75–325 mg) is a mainstay of therapy for patients at high risk of cardiovascular (CV) events. However, in some…”
Get full text

Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors by HAWKEY, Chris, TALLEY, Nicholas J, YEOMANS, Neville D, JONES, Roger, SUNG, Joseph J. Y, LANGSTRÖM, Göran, NAEDAL, Jørgen, SCHEIMAN, James M

“…Upper gastrointestinal (GI) symptoms are common in patients using non-steroidal antiinflammatory drugs (NSAIDs) including selective cyclooxygenase (COX)-2…”
Get full text

Esomeprazole for the Management of Upper Gastrointestinal Symptoms in Patients Who Require NSAIDs: A Review of the NASA and SPACE Double-Blind, Placebo-Controlled Studies by Hawkey, Christopher J., Svedberg, Lars-Erik, Næsdal, Jørgen, Byrne, Claire

“…Background and Objective: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of pain in rheumatic disorders and chronic pain…”
Get full text

W1021 A Single Capsule Formulation of Esomeprazole 40 Mg and Acetylsalicylic Acid 325 Mg Compared with the Monotherapies Given Separately: A Single-Dose Bioequivalence Study in Healthy Subjects by Niazi, Mohammad, Nauclér, Emma, Næsdal, Jørgen

Get full text

Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes by DUNLOP, Simon P, HEBDEN, John, CAMPBELL, Eugene, NAESDAL, Jorgen, OLBE, Lars, PERKINS, Alan C, SPILLER, Robin C

“…Irritable bowel syndrome (IBS) is a heterogeneous condition and defined according to symptoms. Low-grade inflammation has been associated with IBS,…”
Get full text

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies by Hawkey, Christopher J, Talley, Nicholas J, Scheiman, James M, Jones, Roger H, Långström, Göran, Naesdal, Jorgen, Yeomans, Neville D

“…Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 (COX-2) inhibitors, cause upper gastrointestinal (GI) symptoms that are…”
Get full text

T1050 Dyspeptic Symptoms and Sleep Disturbance: A Report from a Large Observational Study in Low-Dose Acetylsalicylic Acid Users by Chappel, Christopher, Neuman, David, Thompson, Vincent J, Pratt, Stephen, Delgado, John P, Elkin, Eric P, Næsdal, Jørgen, Junghard, Ola, Sörstadius, Elisabeth

Get full text

Impact of irritable bowel syndrome on patientsʼ lives: development and psychometric documentation of a disease-specific measure for use in clinical trials by Longstreth, George F, Bolus, Roger, Naliboff, Bruce, Chang, Lin, Kulich, Károly R, Carlsson, Jonas, Mayer, Emeran A, Naesdal, Jörgen, Wiklund, Ingela K

“…OBJECTIVETo develop a disease-specific questionnaire to capture the impact of irritable bowel syndrome (IBS) and its treatment on patientsʼ lives, the…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT 1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome by Drossman, Douglas A., Danilewitz, Mervyn, Naesdal, Jørgen, Hwang, Clara, Adler, John, Silberg, Debra G.

Get full text

The re-bleeding ulcer by Naesdal, Jørgen

Get more information

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid by Moberg, Christina, Naesdal, Jørgen, Svedberg, Lars-Erik, Duchateau, Delphine, Harte, Nicola

“…Background: Low-dose acetylsalicylic acid (ASA; 75-325 mg) is a mainstay of therapy for patients at high risk of cardiovascular (CV) events. However, in some…”
Get full text